Reports
Sale
Global Cytokine Market Analysis, Share, Trends, Forecast: By Cytokine Type: Tumor Necrosis Factor-TNF, Interleukins-II, Interferons-IFN, Epidermal Growth Factor-EGF, Other Cytokine Types; By Application: Cancer, Asthma and Airway Inflammation, Arthritis, Other Therapeutic Applications; Regional Analysis; Supplier Landscape; 2024-2032
Global Cytokine Market Outlook
The global cytokine market size was valued at USD 92.67 million in 2023, driven by the rising prevalence for personalised medicine across the globe. The market is expected to grow at a CAGR of 9.8% during the forecast period of 2024-2032, with the values likely to rise from USD 101.75 million in 2024 to USD 214.96 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Cytokine Market Overview
Cytokine refers to a group of small, short-lived proteins that are released by one cell to regulate the function of another cell, thereby serving as intercellular chemical messengers. Cytokine effect changes in cellular behavior that are important in several physiological processes, including reproduction, growth and development, and injury repair. Cytokines find their application across various therapeutic areas, particularly immunotherapy. Consequently, they are widely used in cancer and autoimmune disorder treatments. As per the data released by American Cancer Society, 2,001,140 new cancer cases and 611,720 cancer deaths are predicted to affect the United States population in 2024. Hence, the cytokine market demand is expected to witness an upswing in the coming years.
The market is driven by increasing application of cytokines in drug development and therapeutics along with rising investments from prominent companies to launch novel products and engage in research and development activities to strengthen their market position.
Increased Application in Cancer Therapeutics
Advancements in bioengineering have significantly helped in a better understanding of cytokine biology. The knowledge spans from receptor binding and cytokine structures, as a result, cytokine-based immunotherapy is becoming increasingly prevalent in recent years. In April 2023, Synthekine Inc., a United States based, engineered cytokine therapeutics company introduced a clinical trial design for orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001. The increasing application of cytokines in cancer therapeutics is poised to enhance the cytokine market share in the forecast period.
Emphasis on Developing Effective Solutions to Address Multiple Indications
In December 2023, Equillium, Inc., announced an update on their multi-cytokine programs EQ101, and EQ102 to treat alopecia areata, celiac disease respectively. EQ101 was well tolerated in the 24-week dosing period in the Phase 2 study for alopecia areata. EQ102, a bi-specific inhibitor of IL-15 and IL-21, two cytokines central to T and B cell activity, is a potential candidate to treat skin and gastrointestinal diseases. Another promising candidate EQ302 (an orally delivered multi-cytokine inhibitor of IL-15 & IL-21) is also under investigation as it offers significant commercial and clinical benefits over EQ102. The increasing research and development activities in cytokines to address several diseases with efficiency and accuracy is poised to boost the cytokine market size during the forecast period.
Advent of New Technologies to Improve the Efficacy of Available Options
The healthcare and biotechnology industry has witnessed various technological advancements in recent years. Technical innovations have led to the emergence of various novel platforms to boost the effectiveness of options available and are anticipated to drive cytokine market growth in the upcoming years. In November 2023, Reverb Therapeutics launched a new Amplifier, an antibody-based platform for treating a broad range of diseases with endogenous cytokines that occur naturally within the body. Financed by Amplitude Ventures and Myeloma Investment Fund, the platform is designed to redirect a cytokine to a specific tumor, immune cell, or tissue, using elements of new and existing antibodies.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Cytokine Market Segmentation
Market Breakup by Cytokine Type
- Tumor Necrosis Factor-TNF
- Interleukins-II
- Interferons-IFN
- Epidermal Growth Factor-EGF
- Other Cytokine Types
Market Breakup by Application
- Cancer
- Asthma and Airway Inflammation
- Arthritis
- Other Therapeutic Applications
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Cytokine Market Regional Analysis
North America is expected to lead the market share for cytokines in the forecast period, which can be attributed to a robust research and development infrastructure in the region. The region is witnessing increased collaborations between key healthcare companies and academic institutions to develop effective and innovative solutions for chronic conditions including cancer, among others. Leveraging latest technologies, there is major focus on engineering T cells to carry cytokines IL-15 and IL-21 on their surface, which enhances their ability to kill cancer cells.
The Asia Pacific region is poised to witness substantial cytokine market growth in the forecast period. In January 2024, researchers from Osaka University discovered a new way to suppress the cytokine release storm (a condition where the body releases too many cytokines leading to inflammation) by blocking the IL-6 signals and minimizing the side effects. The ongoing research indicates that cytokines are a key area of research amongst scientists. In addition, the increasing technological advancements and infrastructure improvement is predicted to boost market growth in the region.
Global Cytokine Market: Competitor Landscape
In May 2023, CytoAgents, Inc., a clinical stage biotech company received FDA’s go ahead to initiate Phase 1b/2a clinical trial for its Investigational New Drug (IND) CTO1681, o treat (cytokine release syndrome) CRS in lymphoma patients receiving CAR T-Cell Therapy. The new drug candidate targets the condition by regulating the body’s natural response to sickness. With the new candidate, the company anticipates accelerating their clinical development efforts.
The key features of the cytokine market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- GSK PLC
- Novartis AG
- Amgen
- Pfizer Inc.
- Sanofi SA
- AstraZeneca plc
- Biocon Limited
- Abbvie Inc
- Johnson and Johnson
- UCB S.A.
- Thermo Fisher Scientific Inc.
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd.
- Sichuan Guoguang agrochemical co. ltd
- TCI Chemicals (India) Pvt. Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Cytokine Type |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cytokine Market Overview
3.1 Global Cytokine Market Historical Value (2017-2023)
3.2 Global Cytokine Market Forecast Value (2024-2032)
4 Global Cytokine Market Landscape
4.1 Global Cytokine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cytokine Product Landscape
4.2.1 Analysis by Cytokine Type
4.2.2 Analysis by Application
5 Global Cytokine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cytokine Market Segmentation
6.1 Global Cytokine Market by Cytokine Type
6.1.1 Market Overview
6.1.2 Tumor Necrosis Factor-TNF
6.1.3 Interleukins-II
6.1.4 Interferons-IFN
6.1.5 Epidermal Growth Factor-EGF
6.1.6 Other Cytokine Types
6.2 Global Cytokine Market by Application
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Asthma and Airway Inflammation
6.2.4 Arthritis
6.2.5 Other Therapeutic Applications
6.3 Global Cytokine Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Cytokine Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cytokine Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cytokine Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Others
10 Latin America Cytokine Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cytokine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding & Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 GSK PLC
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Novartis AG
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Amgen
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Financial Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Sanofi SA
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 AstraZeneca plc
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Biocon Limited
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Abbvie Inc
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Johnson and Johnson
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 UCB S.A.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Thermo Fisher Scientific Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Novo Nordisk A/S
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Teva Pharmaceutical Industries Ltd.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Sichuan Guoguang agrochemical co. ltd
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 TCI Chemicals (India) Pvt. Ltd.
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
19 Global Cytokine Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 92.67 million in 2023, driven by increasing prevalence of personalised medicine across the globe.
The market is anticipated to grow at a CAGR of 9.8% during the forecast period of 2024-2032, likely to reach a market value of USD 214.96 million by 2032.
The market demand is driven by the rising incidence of chronic diseases in the older population, along with rising technical advancements and increased research and development investments.
The application of cytokines to treat multiple diseases is a major market trend. In December 2023, Equillium, Inc., announced the launch of their multi-cytokine programs EQ101, aimed at treating alopecia areata and EQ102 to treat celiac disease. Another promising candidate EQ302 (an orally delivered multi-cytokine inhibitor of IL-15 & IL-21) is also under investigation.
Based on product types, the market is divided into tumor necrosis factor-TNF, interleukins-II, interferons-IFN, and epidermal growth factor-EGF, among others.
Common application areas include cancer, asthma and airway inflammation, and arthritis, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are GSK PLC, Novartis AG, Amgen, Pfizer Inc., Sanofi SA, AstraZeneca plc., Abbvie Inc., Johnson and Johnson, UCB S.A., Thermo Fisher Scientific Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sichuan Guoguang agrochemical co. ltd., TCI Chemicals (India) Pvt. Ltd., and Biocon Limited.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER